RO4893594
Sponsors
F. Hoffmann-La Roche AG
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)Neovascular age-related macular degeneration (nAMD)
Phase 3
A Phase IIIb, Global, Multicenter, Randomized, Visual Assessor−Masked Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (Velodrome)
Active, not recruitingCTIS2023-507130-24-00
Start: 2021-10-22Target: 183Updated: 2025-09-22
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
Active, not recruitingCTIS2023-507131-38-00
Start: 2022-05-16Target: 191Updated: 2025-09-23
A phase IIIb, Multicenter, Single-Arm Study Assessing the Effectiveness, Safety and Patient Reported Outcomes of a 36-week Refill Exchange Regimen for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
RecruitingCTIS2024-516924-32-00
Start: 2025-10-17Target: 164Updated: 2025-09-15